Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: A tissue microarray study

Journal of Clinical Pathology

Volumn 67, Issue 1, 2014, Pages 26-32

  Prins, M J D ^a   Ruurda, J P ^a   Van Diest, P J ^a   Van Hillegersberg, Richard ^a   Ten Kate, F J W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895064418     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201570     Document Type: Article

References (13)

1. Bang YJ, Van CE, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
2. Moelans CB, de Weger RA, van Blokland MT, et al. HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cell Oncol 2009;31:1-10.
3. Prins MJ, Ruurda JP, van Diest PJ, et al. The signi ficance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study. Ann Oncol 2013;24:1290-7.
4. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. (Pubitemid 351724903)
5. Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25:637-50.
6. van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. BMJ 2002;325:648-51.
7. Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-9. (Pubitemid 44315804)
8. Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced in flammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008;26:1066-72.
9. Ellis CM, Dyson MJ, Stephenson TJ, et al. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol 2005;58:710-14. (Pubitemid 40956824)
10. Konsti J, Lundin J, Jumppanen M, et al. A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals. J Clin Pathol 2008;61:278-82. (Pubitemid 351354229)
11. Stevens R, Almanaseer I, Gonzalez M, et al . Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system. J Mol Diagn. 2007;9:144-50. (Pubitemid 47305080)
12. Theodosiou Z, Kasampalidis IN, Livanos G, et al. Automated analysis of FISH and immunohistochemistry images: a review. Cytometry A. 2007;71:439-50. (Pubitemid 47036034)
13. Tubbs RR, Pettay JD, Swain E, et al. Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: a feasibility study. Appl Immunohistochem Mol Morphol 2006;14:436-40. (Pubitemid 44813705)